Targets for Therapy of Bladder Cancer
- 1 March 2020
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 50 (2) , 162-170
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Fractionated intravesical radioimmunotherapy with213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinomaCancer Biology & Therapy, 2015
- Targeting the VEGF pathway in metastatic bladder cancerExpert Opinion on Investigational Drugs, 2015
- Radioimmunotherapy with α-Particle-Emitting RadionuclidesImmunotherapy, 2014
- Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11Clinical Cancer Research, 2014
- Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for TreatmentPLOS ONE, 2013
- Alpha-Particle Emitting 213Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of OxygenationPLOS ONE, 2013
- Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulationNature Biotechnology, 2012
- Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude MiceJournal of Nuclear Medicine, 2009
- Risks to Normal Tissues From Radionuclide TherapySeminars in Nuclear Medicine, 2008
- Expression of the epidermal growth factor receptor family in normal and malignant urotheliumBJU International, 2005